BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 36.55
+3.30 (9.92%)
Aug 15, 2025, 1:30 PM CST
BioGend Therapeutics Market Cap
BioGend Therapeutics has a market cap or net worth of 4.54 billion as of August 15, 2025. Its market cap has decreased by -3.05% in one year.
Market Cap
4.54B
Enterprise Value
4.00B
Revenue
195.02M
Ranking
n/a
PE Ratio
n/a
Stock Price
36.55
Market Cap Chart
Since June 18, 2019, BioGend Therapeutics's market cap has increased from 2.71B to 4.54B, an increase of 67.33%. That is a compound annual growth rate of 8.71%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Aug 15, 2025 | 4.54B | 8.62% |
| Dec 31, 2024 | 4.18B | -11.18% |
| Dec 29, 2023 | 4.71B | 109.50% |
| Dec 30, 2022 | 2.25B | -18.50% |
| Dec 30, 2021 | 2.76B | -22.86% |
| Dec 31, 2020 | 3.57B | 46.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 224.90B |
| PharmaEssentia | 167.97B |
| Bora Pharmaceuticals Co., LTD. | 97.17B |
| Lotus Pharmaceutical | 52.73B |
| Oneness Biotech | 34.00B |
| Lumosa Therapeutics | 28.78B |
| Polaris Group | 27.23B |
| Center Laboratories | 26.78B |